Cantor Fitzgerald Initiates Coverage On Camp4 Therapeutics with Overweight Rating, Announces Price Target of $7
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight rating and announces Price Target of $7.
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight rating and announces Price Target of $7.